|
Name |
Aniquinazoline C
|
Molecular Formula | C27H31N5O5 | |
IUPAC Name* |
(1S,4R)-1-hydroxy-4-[2-hydroxy-2-[(2R,4S)-5-oxo-1-phenyl-4-propan-2-ylimidazolidin-2-yl]propyl]-1-methyl-2,4-dihydropyrazino[2,1-b]quinazoline-3,6-dione
|
|
SMILES |
CC(C)[C@H]1C(=O)N([C@@H](N1)C(C)(C[C@@H]2C(=O)N[C@@](C3=NC4=CC=CC=C4C(=O)N23)(C)O)O)C5=CC=CC=C5
|
|
InChI |
InChI=1S/C27H31N5O5/c1-15(2)20-23(35)31(16-10-6-5-7-11-16)24(29-20)26(3,36)14-19-21(33)30-27(4,37)25-28-18-13-9-8-12-17(18)22(34)32(19)25/h5-13,15,19-20,24,29,36-37H,14H2,1-4H3,(H,30,33)/t19-,20+,24-,26?,27+/m1/s1
|
|
InChIKey |
ALKYEXCSBFPRPV-ALXWUKCCSA-N
|
|
Synonyms |
Aniquinazoline C
|
|
CAS | NA | |
PubChem CID | 139587840 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 505.6 | ALogp: | 1.6 |
HBD: | 4 | HBA: | 7 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 135.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 37 | QED Weighted: | 0.415 |
Caco-2 Permeability: | -5.442 | MDCK Permeability: | 0.00001910 |
Pgp-inhibitor: | 0.922 | Pgp-substrate: | 0.138 |
Human Intestinal Absorption (HIA): | 0.041 | 20% Bioavailability (F20%): | 0.028 |
30% Bioavailability (F30%): | 0.018 |
Blood-Brain-Barrier Penetration (BBB): | 0.065 | Plasma Protein Binding (PPB): | 68.49% |
Volume Distribution (VD): | 0.692 | Fu: | 33.71% |
CYP1A2-inhibitor: | 0.026 | CYP1A2-substrate: | 0.247 |
CYP2C19-inhibitor: | 0.059 | CYP2C19-substrate: | 0.726 |
CYP2C9-inhibitor: | 0.248 | CYP2C9-substrate: | 0.259 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.112 |
CYP3A4-inhibitor: | 0.527 | CYP3A4-substrate: | 0.922 |
Clearance (CL): | 4.364 | Half-life (T1/2): | 0.329 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.949 |
Drug-inuced Liver Injury (DILI): | 0.989 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.015 | Maximum Recommended Daily Dose: | 0.879 |
Skin Sensitization: | 0.087 | Carcinogencity: | 0.038 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.703 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003666 | 0.788 | D0B1FE | 0.319 | ||||
ENC003601 | 0.637 | D07VHR | 0.313 | ||||
ENC002409 | 0.589 | D0QV5T | 0.296 | ||||
ENC004645 | 0.525 | D0E3OF | 0.295 | ||||
ENC004348 | 0.496 | D0J5YC | 0.293 | ||||
ENC002127 | 0.466 | D0J6WW | 0.288 | ||||
ENC001948 | 0.466 | D06ZPS | 0.288 | ||||
ENC004647 | 0.455 | D0E4DW | 0.287 | ||||
ENC004267 | 0.455 | D03DEI | 0.283 | ||||
ENC002940 | 0.449 | D0J5VR | 0.280 |